Annual Drug Patent Expirations for TRIUMEQ+PD
Triumeq Pd is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.
Drug patent litigation for TRIUMEQ PD.
This drug has one hundred and twenty-four patent family members in thirty-three countries.
The generic ingredient in TRIUMEQ PD is abacavir sulfate; dolutegravir sodium; lamivudine. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
